BioLineRx Ltd.
No SEC Form 4 filings for $BLRX in the last 30 days.
See all $BLRX insider activity →BioLineRx (BLRX) shares fell 4.4% premarket after announcing a $3.75M share offering at $2.78 per ADS, below recent trading levels. The company plans to use proceeds for R&D and corporate purposes. The offering includes warrants for additional shares and is expected to close by August 31, 2026. BLRX is developing therapies in oncology and rare diseases, with its lead asset in a Phase 1/2a trial.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced a $3.75M registered direct offering of 1.35M ADSs at $2.78 each, with warrants for 2.02M more. Proceeds will fund R&D and working capital. Closing expected Aug 31, 2026. The company also amended outstanding warrants, reducing the exercise price to $2.78 and extending expiration to 2031.
BioLineRx Ltd. director Sandra Panem filed an initial ownership report, Form 3, detailing a significant number of employee stock options to purchase ordinary shares. These options include various blocks with different exercise prices and expiration dates ranging from 2026 to 2034. Footnotes indicate that older grants through 2024 are fully vested, while a substantial portion of a more recent October 2024 grant will vest quarterly, conditional on continued service.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BLRX (BioLineRx Ltd.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent BLRX coverage spans financial news and corporate actions.
Dilutive capital raise may pressure share price in the short term.
The modest capital raise provides short‑term liquidity for R&D but is unlikely to move the stock significantly.
The director's significant stock option grants suggest potential future insider activity, possibly signaling confidence in the company's long-term prospects.
The filing reveals significant stock options granted to a director, with a substantial number vested and the remainder vesting over time. This insider activity may signal confidence in the company's future performance.
BioLineRx's full arbitration victory diminishes legal risks and may positively influence investor confidence, possibly leading to a short-term stock price increase.
alphai scores every news story that mentions BLRX with an AI model for sentiment and relevance, and aggregates insider trades from BioLineRx Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioLineRx (BLRX) shares fell 4.4% premarket after announcing a $3.75M share offering at $2.78 per ADS, below recent trading levels. The company plans to use proceeds for R&D and corporate purposes. The offering includes warrants for additional shares and is expected to close by August 31, 2026. BLRX is developing therapies in oncology and rare diseases, with its lead asset in a Phase 1/2a trial.
2 min readBioLineRx (NASDAQ: BLRX) (TASE: BLRX) announced a $3.75M registered direct offering of 1.35M ADSs at $2.78 each, with warrants for 2.02M more. Proceeds will fund R&D and working capital. Closing expected Aug 31, 2026. The company also amended outstanding warrants, reducing the exercise price to $2.78 and extending expiration to 2031.
1 min readBioLineRx Ltd. director Sandra Panem filed an initial ownership report, Form 3, detailing a significant number of employee stock options to purchase ordinary shares. These options include various blocks with different exercise prices and expiration dates ranging from 2026 to 2034. Footnotes indicate that older grants through 2024 are fully vested, while a substantial portion of a more recent October 2024 grant will vest quarterly, conditional on continued service.
2 min readBioLineRx Ltd. director Cohen Gal Avraham has filed an initial ownership report detailing employee stock options for 2,055,000 ordinary shares. These options have an exercise price of $0.052 per share and expire on August 14, 2034, granted under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remainder vesting in seven equal quarterly installments, subject to continued service.
2 min readBioLineRx secured a full arbitration victory in a dispute with Biokine Therapeutics over alleged unpaid amounts related to a motixafortide licensing agreement. The arbitrator denied Biokine's $7.2 million claim and awarded BioLineRx legal expenses, resolving a financial and legal uncertainty for the biopharmaceutical company. This decision strengthens BioLineRx's financial position and clarifies its obligations regarding the motixafortide program.
3 min readORR was 64% and DCR reached 91% in the motixafortide combo group vs. historical 23% ORR and 48% DCR with standard therapy. Four of eleven patients in the pilot study remained progression-free for over one year following treatment.
3 min read
